Literature DB >> 3944766

Disposition of 8-methoxypsoralen in the rat: methodology for measurement, dose-dependent pharmacokinetics, tissue distribution and identification of metabolites.

D C Mays, S L Rogers, R C Guiler, D E Sharp, S G Hecht, A E Staubus, N Gerber.   

Abstract

The pharmacokinetics and metabolism of 8-methoxypsoralen (8-MOP) were measured in the catheterized rat after a single i.v. dose. Blood samples were collected serially and analyzed using a sensitive and specific assay for [14C]-8-MOP. Total body clearance of 8-MOP was 7.3, 3.9, 1.7, 1.0, 0.78 and 0.42 liters/kg/hr at doses of 0.2, 1.0, 2.5, 5.0, 10 and 20 mg/kg, respectively. The decline in total body clearance indicates that elimination of 8-MOP is dose-dependent in the rat. After i.v. administration of 10 mg/kg of 8-MOP, 71 and 26% of the dose was recovered within 72 hr in the urine and feces, respectively. Unchanged 8-MOP accounted for less than 1% of the excreted radioactivity. In tissue distribution studies at 0.5, 2 and 5 hr after i.v. administration, 8-MOP distributed rapidly to all tissues and concentrated in the fat and kidneys. The concentration of 8-MOP in the skin was 0.4 to 0.6 times that in the blood. Eleven metabolites of 8-MOP were detected in the urine. The metabolites identified after enzymatic hydrolysis were 8-hydroxypsoralen; 5-hydroxy-8-methoxypsoralen; 5,8-dihydroxypsoralen; 5,8-dioxopsoralen; 6-(7-hydroxy-8-methoxycoumaryl)-acetic acid and 8-MOP (formed by ring closure of a coumaric acid metabolite). Thus, these studies indicate that 8-MOP is metabolized in the rat by 1) O-demethylation; 2) hydroxylation at position 5; 3) hydrolysis of the lactone ring and 4) oxidation of the furan ring, a pathway already confirmed in insects, dogs and humans.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3944766

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

1.  Identification of phase-I metabolites and chronic toxicity study of the Kv1.3 blocker PAP-1 (5-(4-phenoxybutoxy)psoralen) in the rat.

Authors:  B Hao; Z-W Chen; X-J Zhou; P I Zimin; G P Miljanich; H Wulff; Y-X Wang
Journal:  Xenobiotica       Date:  2010-11-11       Impact factor: 1.908

2.  Fate of [(14)C]xanthotoxin (8-methoxypsoralen) in laying hens and a lactating goat.

Authors:  N C Pangilinan; G W Ivie; B A Clement; R C Beier; M Uwayjan
Journal:  J Chem Ecol       Date:  1992-02       Impact factor: 2.626

3.  Transcutaneous sampling of ciprofloxacin and 8-methoxypsoralen by electroporation (ETS technique).

Authors:  Srinivasa M Sammeta; Siva Ram K Vaka; S Narasimha Murthy
Journal:  Int J Pharm       Date:  2008-11-05       Impact factor: 5.875

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.